Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus (Q43511956)

24 November 2017

Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus (English)

1 reference

24 November 2017

0 references

1 reference

4

1 reference

24 November 2017

5

1 reference

24 November 2017

2

Manmohan Parida

1 reference

24 November 2017

Mugdha Tiwari

1

1 reference

24 November 2017

S R Santhosh

series ordinal

3

1 reference

24 November 2017

P V Lakshmana Rao

series ordinal

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

27 February 2009

1 reference

24 November 2017

1 reference

24 November 2017

27

1 reference

24 November 2017

18

1 reference

24 November 2017

2513-2522

1 reference

East Central South African genotype as the causative agent in reemergence of Chikungunya outbreak in India

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Infection with chikungunya virus in Italy: an outbreak in a temperate region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

A single mutation in chikungunya virus affects vector specificity and epidemic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Immunologic interference from sequential administration of live attenuated alphavirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Development of an attenuated strain of chikungunya virus for use in vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Development and evaluation of SYBR Green I-based one-step real-time RT-PCR assay for detection and quantification of Chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Rapid chemosensitivity assay with human normal and tumor cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Allergic mucocutaneous reactions to Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Growth of Cell-strains and Primary Cells on Micro-carriers in Homogeneous Culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Evaluation of the serum-free medium MDSS2 for the production of poliovirus on vero cells in bioreactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Application of a serum-free medium for the growth of Vero cells and the production of reovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Why do we not have an HIV vaccine and how can we make one? .

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Regulation of cytokine gene expression by adjuvants in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

Detection of alphaviruses in a genus-specific antigen capture enzyme immunoassay using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.062

10.1016/J.VACCINE.2009.02.062

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference